What the evidence says
Reported, not advice: each line is from a published trial, a label or the FDA, quoted in full below. Which medicine suits you is a decision for you and your prescriber.
Approval
Compounded drugs are not FDA-approved, so the FDA does not review them for safety, effectiveness or quality before they are sold.
FDA, concerns with unapproved GLP-1 drugs used for weight lossZepbound's evidence
In SURMOUNT-5, tirzepatide at 10 or 15 mg cut weight by 20.2% over 72 weeks.
SURMOUNT-5, N Engl J Med 2025;393:26-36 (PubMed abstract)Where to get each, cheapest first
Compounded tirzepatide · 22 programs
- WellmedrBlack Friday saleCompounded Tirzepatide$71/moPre-Black Friday sale: semaglutide from $41/mo, tirzepatide from $71/momembership fee not verifiedCheck price on Wellmedr’s site ↗Full breakdown
- CollectiveCompounded TirzepatideTrustpilot4.8 (288 reviews)$85/mo21-day free membership trialfirst 21 days of membership free$69 + $16 membershipCheck price on Collective’s site ↗Full breakdown
- EmbodyBlack Friday saleCompounded TirzepatideTrustpilot3.9 (11.8k reviews)$99/moPre-Black Friday sale: $49/mo on the 12-month plantirzepatide $99/mo on the same planno membership fee · $1,188 due up frontCheck price on Embody’s site ↗Full breakdown
Zepbound · 5 programs
- Lemonaid HealthZepbound vial (brand tirzepatide, via LillyDirect)Trustpilot4.2 (192 reviews)$348/moFirst month of membership freefirst month of membership free$299 + $49 membershipCheck price on Lemonaid Health’s site ↗Full breakdown
- Sesame CareZepbound KwikPen (brand tirzepatide)Trustpilot4.6 (4.6k reviews)$358/moWegovy or Ozempic $199/mo for the first two months$299 + $59 membershipCheck price on Sesame Care’s site ↗Full breakdown
- Mochi HealthZepbound (brand tirzepatide)$378/moFirst month of membership free$79 off membership on the 1-month plan$299 + $79 membershipCheck price on Mochi Health’s site ↗Full breakdown
Common questions
What is the difference between Compounded tirzepatide and Zepbound?
Both use tirzepatide as the active ingredient. Zepbound is the FDA-approved product; compounded tirzepatide is mixed by a pharmacy, usually costs less, is not FDA-approved, and is not FDA-reviewed for safety, effectiveness or quality.
Which is cheaper, Compounded tirzepatide or Zepbound?
Compounded tirzepatide, this week: from $71 a month all-in at Wellmedr, against $348 for Zepbound at Lemonaid Health. That is $277 a month, $3,324 a year.
What is Compounded tirzepatide approved for?
Not FDA-approved for anything. Compounded, not FDA-approved, taken as a weekly injection from a vial.
What is Zepbound approved for?
Weight loss; sleep apnea with obesity. FDA-approved brand, taken as a weekly injection.
Where these facts come from
We track prices. Every clinical and manufacturer claim about Compounded tirzepatide and Zepbound on this page is quoted here in its source’s own words, with the date we read it. We do not write medical guidance and we do not tell anyone what dose to take.
2 sources · read November 2026
- 01read November 2026
FDA, concerns with unapproved GLP-1 drugs used for weight losscompounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.
… FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products.
- 02read November 2026
SURMOUNT-5, N Engl J Med 2025;393:26-36 (PubMed abstract)adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.
… The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).
… The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation.
… (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.)









